Clinical trials: Neurocognitive Disorders, Mild
Alzheimer's Disease, Mild Cognitive Impairment
Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.
When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination.
- Trial name
- NCT02309723
- Testing
- Beta amyloid imaging
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Alzheimer's Disease
Neural Correlates In Mild Alzheimer's Disease
The objective of this study was to identify neural correlates of cognitive improvement after 3 months of donepezil hydrochloride treatment using either or both of two functional magnetic resonance imaging (fMRI) measures - the…
- Trial name
- NCT00477659
- Testing
- Donepezil hydrochloride
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks.
- Trial name
- RETHINK-ALZ (NCT04994483)
- Testing
- Simufilam
- Where
- 88 sites in United States, Australia and 1 more
- Volunteers
- 804 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer's Disease
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARSHINE (NCT01955161)
- Testing
- Idalopirdine
- Where
- 137 sites in United States, Argentina and 14 more
- Volunteers
- 933 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease, Mild Cognitive Impairment
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among…
- Trial name
- NCT04730635
- Testing
- Donepezil
- Where
- 10 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis, Alzheimer Disease
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NADALS (NCT05189106)
- Testing
- Baricitinib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Mild Cognitive Impairment
A Scalable Model for Promoting Functioning and Well-Being Among Older Adults With Mild Cognitive Impairment Via Meaningful Social Interactions: Project SPEAK!
The goal of this study is to refine and test a strategy for engaging older adults with symptoms of SCD/MCI (subjective cognitive decline/mild cognitive impairment) as volunteers to help English language learners (ELLs) who live…
- Trial name
- NCT04717479
- Testing
- Intervention (videoconferencing)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Aging, Cognitive Aging
Impact of Music Improvisation Training on Cognitive Function in Older Adults
This project will develop and test the effects and mechanisms of a music improvisation training intervention on self-regulation of older adults with and without MCI.
- Conditions
- Aging, Cognitive Aging, Cognitive Impairment, Cognitive Training
- Trial name
- NCT05980286
- Testing
- Piano Improvisation, Music Listening
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Insomnia, Mild Cognitive Impairment
SleepSMART for Veterans With MCI and Insomnia
Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for chronic insomnia. However, cognitive impairments may limit progress in CBT-I for older Veterans with Mild Cognitive Impairment (MCI).
- Trial name
- SleepSMART (NCT05016960)
- Testing
- Sleep-SMART
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Alzheimer Disease, Cognitive Dysfunction
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (MCI) or mild dementia due to…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
- Trial name
- NCT04602624
- Testing
- SAGE-718
- Where
- 10 sites in United States
- Volunteers
- 26 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Mild Cognitive Impairment, Adherence, Patient
MI-CBT Adherence Program for Lifestyle Interventions in Older Adults
Objective 1: Assess feasibility and acceptability of all protocol components of a pilot trial testing a 6-week telehealth Mediterranean ketogenic nutrition adherence (KNA) program using motivational interviewing and cognitive…
- Conditions
- Mild Cognitive Impairment, Adherence, Patient, Ketosis
- Trial name
- MI-CBT KNAP (NCT04817176)
- Testing
- Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program, Ketogenic Nutrition Program
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Florida State University
Mild to Moderate Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT03507790
- Testing
- CT1812
- Where
- 32 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- Cognition Therapeutics
Alzheimer Disease
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
- Trial name
- NCT00397891
- Testing
- bapineuzumab
- Where
- 4 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Mild Cognitive Impairment
Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation
Patients with amnestic mild cognitive impairment (MCI) often have compromised quality of life (QOL). Cognitive impairment is a major contributor to decrements in QOL and progression of MCI often leads to loss of independence and…
- Trial name
- TVNS MCI (NCT03359902)
- Testing
- Transcutaneous vagal nerve stimulation
- Where
- 3 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of Florida
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Dementia, Mild Cognitive Impairment
Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia
The AMOR-Kentucky study will examine the impact of a pharmacist-physician patient-centered medication therapy management deprescribing intervention to address inappropriate medication use in patients with cognitive impairment in…
- Trial name
- AMOR-KY (NCT05078437)
- Testing
- Medication therapy management
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Daniela Moga
Mild Cognitive Impairment, Amnestic Mild Cognitive Impairment - aMCI
Cognitive Outcomes of Brain Stimulation As a Later-in-Life Treatment
This is a pilot study being done to attempt to improve episodic memory problems in persons with mild cognitive impairment (MCI).
- Trial name
- COBALT (NCT05564715)
- Testing
- NeuroElectric StarStim
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Dementia, Alzheimer Disease
The Cognition and Flow Study
About the research There are currently 850,000 people living with dementia in the United Kingdom. It is now understand that Alzheimer's disease (AzD) can result from damaged blood vessels in the brain.
- Conditions
- Dementia, Alzheimer Disease, Mild Cognitive Impairment, Aging
- Trial name
- NCT03656107
- Testing
- Cognitive Training
- Where
- 2 sites in United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Alzheimer's Disease (AD)
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- Abroad (NCT05771428)
- Testing
- ABBV-552
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 263 people
- Sponsor
- AbbVie